New website Launches €1.2 Million Project to Improve European Cancer Communications

An initiative to boost cancer prevention, treatment and care throughout Europe by improving communications within the cancer community kicks off yesterday (Monday 20 July) with the launch of a new website. The project will involve all those with an interest in cancer, from researchers and doctors to patients.

The Eurocancercoms project is an initiative of the European Institute of Oncology and is led by ECCO - the European CanCer Organisation and ecancermedicalscience (an online, open access journal). It is funded by a €1.2 million grant from the European Commission's FP7 programme. The aim is to establish a single, efficient network for cancer communication in Europe, and the new website plays a key role in this ambitious initiative.

Professor Alexander M.M. Eggermont, president of ECCO, explained: "There is an urgent need in Europe to improve communications between everyone working in cancer and between them and patients. Europe has an increasing number of cancer patients and worse outcomes for care, despite having better quality clinical research than the USA. Cancer survival is unacceptably variable in different European countries. A previous study (EUROCAN+PLUS) identified poor communication between all those involved in cancer care as one of the main reasons for these poor outcomes. Eurocancercoms aims to address these problems by creating a 'one-stop shop' for the whole cancer community from scientists to patients."

The principal investigator of Eurocancercoms is Professor Umberto Veronesi, scientific director of the European Institute of Oncology in Milan. Professor Eggermont and Professor Gordon McVie (founding editor of ecancermedicalscience) are leading the project, while Richard Sullivan, Professor at King's Health Partners Integrated Cancer Centre at King's College London (UK), is the project manager.

Eurocancercoms will look at issues surrounding the communication and dissemination of cancer information across Europe, identify the bottlenecks and suggest solutions. It will do this by:

  • examining the flow of information between basic scientists and other healthcare professionals
  • assessing the way cancer research results are disseminated and identifying the existing barriers to successful dissemination
  • establishing searchable databases for clinical trials and guidelines that are available to all involved in cancer care, including patients
  • using new technologies, particularly internet-based technologies, to create a networked cancer community, including health professionals, patients, consumer groups and industry
  • writing policies for promoting the best ways of disseminating cancer science across Europe.

Prof Sullivan, who also heads the European Cancer Managers' Forum which examines cancer research and funding in Europe, said: "I think this is a unique opportunity for cancer in Europe. It is a marvellous opportunity to understand what are the key issues in cancer communication and to create novel ways of getting information out to both the professionals and the patients.

"This will be the first time that lots of very large groups involved in cancer in Europe have come together to improve cancer communications. There's no doubt that people of all ages and demographic profiles are using the internet, including cancer professionals. We need to understand 21st century communications, particularly electronic communications. For instance, at the moment the way we communicate with patients is still the classical method of putting leaflets in doctors' surgeries; but patients are not picking these up any more; they are going online and finding information on the web and through social networking sites. People are changing and electronic resources are the future. We are working in a different world and the way that we work has to reflect this."

He concluded: "Eurocancercoms will build on Europe's strengths in terms of existing cancer networks, cancer information websites and so on. Europe is very diverse, but we will be able to network all these different sources of information together and that's what makes Eurocancercoms unique. It's ambitious but we wouldn't be doing it if we didn't think we could deliver."

For further information, please visit:
http://www.eurocancercoms.eu

ECCO - the European CanCer Organisation - exists to uphold the right of all European cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. For more information, visit: www.ecco-eu.org

ecancermedicalscience is an open access cancer journal founded by the European Institute of Oncology in Milan (www.ieo.it). For more information, visit: www.ecancermedicalscience.com

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...